DBV Technologies Demonstrates Ability of VIASKIN® to Administer Allergen via Intact Skin by Targeting Dendritic Cells for Safe Treatment of Allergic Disease

PARIS--(BUSINESS WIRE)--DBV Technologies, an emerging biotechnology company, announced today that a study1—“Epicutaneous Immunotherapy (EPIT) Results in Rapid Allergen Uptake by Dendritic Cells through Intact Skin and Downregulates the Allergen-Specific Response in Mice“—published in the Journal of Immunology confirms the safety of the Company’s VIASKIN® epicutaneous immunotherapy (EPIT) approach to desensitizing against peanut allergy via a novel and patented skin patch.

Back to news